Poor graft function after T cell-depleted allogeneic hematopoietic stem cell transplant

被引:6
|
作者
Reich-Slotky, Ronit [1 ]
Al-Mulla, Naima [2 ]
Hafez, Rania [3 ]
Segovia-Gomez, Javier [4 ]
Goel, Ruchika [5 ,6 ]
Mayer, Sebastian [7 ]
Phillips, Adrienne [7 ]
Shore, Tsiporah B. [7 ]
Hsu Jing-Mei [7 ]
Hsu, Yen-Michael Sheng [7 ]
Vasovic, Ljiljana V. [7 ]
Cushing, Melissa M. [7 ]
Gergis, Usama [7 ]
机构
[1] Hackensack Univ, Med Ctr, Hackensack, NJ USA
[2] Hamad Med Corp, Doha, Qatar
[3] Assiut Univ, Sch Med, Assiute, Egypt
[4] Cent Mil Hosp Bogota, Bogota, Colombia
[5] Johns Hopkins Univ, Dept Pathol, Div Transfus Med, Baltimore, MD USA
[6] Simmons Canc Inst, SIU Sch Med, Springfield, IL USA
[7] Weill Cornell Med Coll, Pathol, New York Presbyterian Hosp, New York, NY USA
关键词
PGF; delayed hematopoietic recovery; poor graft function; CORD BLOOD TRANSPLANTATION; BONE-MARROW; ABO INCOMPATIBILITY; PLATELET RECOVERY; HOST-DISEASE; DONOR; HLA; IMPACT; OUTCOMES; APLASIA;
D O I
10.1080/10428194.2020.1789622
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PGF implies persistent cytopenia in the presence of predominant donor chimerism. We examined contributors to PGF in 104 HCT recipients who survived >= 100 days without relapse or major complications. Surrogate parameters for PGF were: Hg <10 g/dl, RBC transfusion dependence, platelet count <20 x 10(9)/L or ANC < 0.5 x 10(9)/L. All patients received T cell depletion with alemtuzumab or ATG. The 2-year OS and PFS probabilities were 66%, 95%CI (56 - 75%) and 51%, 95%CI (41-60%) respectively. Fifty-four patients (52%) met one or more PGF criteria. There was significant association between major ABO incompatibility and platelet <20 x 109/L (OR = 4.7, 95%CI 1.05-21.26,p = .043), acute GVHD and Hg <10 g/dl (OR 3.7, 95%CI 1.4-9.6,p = .005) and CMV viremia and ANC < 0.5 x 10(9)/L (OR 3.0, 95% CI 1.0, 8.7,p = .043). NRM was significantly higher in the PGF group compared to patients with adequate graft function (45.5% vs 16.7%,p = .014).
引用
下载
收藏
页码:2894 / 2899
页数:6
相关论文
共 50 条
  • [21] Minimizing graft rejection in allogeneic T cell-depleted bone marrow transplantation
    Rigden, JP
    Cornetta, K
    Srour, EF
    Hanna, M
    Broun, ER
    Hromas, R
    Baute, J
    Hilton, J
    Cox, E
    Rubin, L
    Gonin, R
    Tricot, G
    BONE MARROW TRANSPLANTATION, 1996, 18 (05) : 913 - 919
  • [22] Complications after T-CELL depleted allogeneic hematopoietic stem cell transplantation (HSCT).
    Bieri, S
    Roosnek, E
    Helg, C
    Ozsahin, H
    Wacker, P
    Chapuis, B
    Miralbell, R
    Chalandon, Y
    STRAHLENTHERAPIE UND ONKOLOGIE, 2005, 181 : 141 - 141
  • [23] Poor immune reconstitution after four or five major HLA antigens mismatched T cell-depleted allogeneic and autologous stem cell transplantation
    Mattsson, J
    Uzunel, M
    Remberger, M
    Tammik, L
    Omazic, B
    Levitsky, V
    Zou, JZ
    Hentschke, P
    Ringdén, O
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2001, 123 (01): : 162 - 169
  • [24] T-cell depleted allogeneic hematopoietic stem cell transplant for the treatment of Fanconi anemia and MDS/AML
    Satty, Alexandra M.
    Klein, Elizabeth
    Mauguen, Audrey
    Kunvarjee, Binni
    Boelens, Jaap Jan
    Cancio, Maria
    Curran, Kevin J.
    Kernan, Nancy A.
    Prockop, Susan E.
    Scaradavou, Andromachi
    Spitzer, Barbara
    Tamari, Roni
    Ruggiero, Julianne
    Torok-Castanza, Joanne
    Mehta, Parinda A.
    O'Reilly, Richard J.
    Boulad, Farid
    BONE MARROW TRANSPLANTATION, 2024, 59 (01) : 23 - 33
  • [25] T-cell depleted allogeneic hematopoietic stem cell transplant for the treatment of Fanconi anemia and MDS/AML
    Alexandra M. Satty
    Elizabeth Klein
    Audrey Mauguen
    Binni Kunvarjee
    Jaap Jan Boelens
    Maria Cancio
    Kevin J. Curran
    Nancy A. Kernan
    Susan E. Prockop
    Andromachi Scaradavou
    Barbara Spitzer
    Roni Tamari
    Julianne Ruggiero
    Joanne Torok-Castanza
    Parinda A. Mehta
    Richard J. O’Reilly
    Farid Boulad
    Bone Marrow Transplantation, 2024, 59 : 23 - 33
  • [26] Recent advances in haploidentical hematopoietic stem cell transplantation using ex vivo T cell-depleted graft in children and adolescents
    Im, Ho Joon
    Koh, Kyung-Nam
    Seo, Jong Jin
    BLOOD RESEARCH, 2016, 51 (01) : 8 - 16
  • [27] Improved outcome after T-cell depleted allogeneic hematopoietic stem cell transplantation for myelofibrosis
    Simonetta, F.
    Casini, A.
    Wilk, M.
    Ecsedi, M.
    Andres, M.
    Gerull, S.
    Masouridi-Levrat, S.
    Beauverd, Y.
    Mohty, B.
    Bucher, C.
    Stern, M.
    Manz, M.
    Nair, G.
    Schanz, U.
    Passweg, J.
    Chalandon, Y.
    BONE MARROW TRANSPLANTATION, 2016, 51 : S292 - S292
  • [28] Selective T cell-depleted haploidentical hematopoietic stem cell transplantation for relapsed/refractory neuroblastoma
    Liu, Anthony P. Y.
    Lee, Pamela P. W.
    Kwok, Janette S. Y.
    Leung, Rock Y. Y.
    Chiang, Alan K. S.
    Ha, Shau-Yin
    Cheuk, Daniel K. L.
    Chan, Godfrey C. F.
    PEDIATRIC TRANSPLANTATION, 2018, 22 (06)
  • [29] Iron Overload Results in Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation By Impairing Hematopoiesis
    Yang, Ting
    Wu, Xueqiong
    Xiao, Min
    Zhang, Yuxin
    Chen, Zhizhe
    Hu, Jianda
    BLOOD, 2017, 130
  • [30] Poor graft function after allogeneic hematopoietic stem cell transplantation-an old complication with new insights
    Kong, Yuan
    SEMINARS IN HEMATOLOGY, 2019, 56 (03) : 215 - 220